UBS Group AG raised its stake in MediWound Ltd. (NASDAQ:MDWD – Free Report) by 90.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,057 shares of the biopharmaceutical company’s stock after acquiring an additional 68,756 shares during the quarter. UBS Group AG’s holdings in MediWound were worth $2,678,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of the business. Rhumbline Advisers boosted its stake in shares of MediWound by 4.4% in the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 481 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in shares of MediWound by 2.3% in the 3rd quarter. ARK Investment Management LLC now owns 96,879 shares of the biopharmaceutical company’s stock valued at $1,746,000 after purchasing an additional 2,209 shares during the last quarter. Institutional investors own 46.83% of the company’s stock.
MediWound Stock Performance
Shares of MDWD opened at $16.68 on Wednesday. MediWound Ltd. has a twelve month low of $14.90 and a twelve month high of $22.50. The firm’s 50 day moving average price is $16.79 and its two-hundred day moving average price is $17.51. The firm has a market cap of $214.34 million, a P/E ratio of -7.94 and a beta of 0.21.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on MDWD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, MediWound has an average rating of “Hold” and a consensus price target of $35.00.
Get Our Latest Stock Report on MediWound
About MediWound
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.
Read More
- Five stocks we like better than MediWound
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediWound Ltd. (NASDAQ:MDWD – Free Report).
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
